Myelosuppressive chemotherapy: must not have received within  weeks of entry onto this study
Patients with solid tumors must not have received myelosuppressive chemotherapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)
Patients must not have received myelosuppressive therapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)
Myelosuppressive chemotherapy: must not have received within  weeks of registration onto this study ( weeks if prior nitrosourea)
Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least  days prior to study registration or at least six weeks if nitrosourea; at least two weeks must have lapsed if patients received lower dose oral etoposide ( mg/) without experiencing evidence of myelosuppression (i.e. neutropenia or requiring transfusion with blood products)
Myelosuppressive chemotherapy: Must not have received within  weeks of entry onto this study ( weeks if prior nitrosourea)
Myelosuppressive chemotherapy: Must not have received within  weeks of enrollment onto this study ( weeks if prior nitrosourea)
Patients must not have received myelosuppressive chemotherapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea).
Myelosuppressive chemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosourea
Myelosuppressive chemotherapy: Must not have received within  weeks of enrollment onto this study ( weeks if prior nitrosourea).
Patients must have received their last dose of known myelosuppressive anticancer therapy at least three () weeks prior to study enrollment or at least six () weeks if prior nitrosourea
INCLUSION CRITERIA FOR STRATUM C: Patients must have received their last dose of known myelosuppressive anticancer therapy at least three () weeks prior to study enrollment or at least six () weeks if prior nitrosourea
Chemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three () weeks prior to study enrollment in the study or at least six () weeks for those receiving nitrosourea
Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosourea
Myelosuppressive chemotherapy: must not have received within  weeks of entry onto this study
Patients must not have received myelosuppressive chemotherapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)
Patients must not have received myelosuppressive therapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)
Chemotherapy: \r\n* Must not have received myelosuppressive chemotherapy within  weeks of the study entry ( weeks if prior nitrosourea); prior treatment with either dasatinib or temsirolimus but not both is allowed; at least  weeks must have elapsed from the last dose
Myelosuppressive chemotherapy: must not have received within  weeks of enrollment onto this study ( weeks if prior nitrosourea)
Must not have received myelosuppressive chemotherapy and/or biologics within  weeks of entry onto this study ( weeks if prior nitrosourea)
Myelosuppressive chemotherapy: Must not have received within  weeks of enrollment onto this study ( weeks if prior nitrosourea).
Evidence of recovery from any prior chemotherapy; no myelosuppressive anticancer chemotherapy or biological therapy within  weeks ( weeks if a nitrosourea or mitomycin C agent) prior to registration
Myelosuppressive chemotherapy: must not have received within  weeks of entry onto this study
Myelosuppressive chemotherapy: Must not have received within  weeks ( weeks if prior nitrosourea)
Myelosuppressive chemotherapy:\r\n* Subjects must have received their last dose of known myelosuppressive anticancer chemotherapy at least three () weeks prior to study registration or at least six () weeks if nitrosourea
Myelosuppressive chemotherapy: interval >=  weeks and >=  weeks from last dose of nitrosourea and other chemotherapy drugs before study enrollment, respectively; however, interval must be >=  week from last dose of oral etoposide and other drugs administered at low doses (metronomic regimen) before study enrollment
Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three () weeks prior to study registration or at least six () weeks if nitrosourea
Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within  weeks of enrollment ( weeks if prior nitrosourea)
Patients must not have received myelosuppressive therapy within  weeks of enrollment onto this study ( weeks if prior nitrosourea)
Chemotherapy: Must not have received myelosuppressive chemotherapy within  weeks prior to study entry ( weeks if prior nitrosourea)
Patient must not have had myelosuppressive chemotherapy =<  weeks prior to entry onto this study (or  weeks if prior nitrosourea)